Kazia Therapeutics Ltd ADR美股招股说明书(2026-04-13版)

PROSPECTUS SUPPLEMENT(to Prospectus dated December 23, 2025) 232,956 American Depositary Shares representing116,478,000Ordinary Shares This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23,2025 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-290598), as amended,with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on April 13,2026 (the “April 13, 2026 Form 6-K”). Accordingly, we have attached the April 13, 2026 Form 6-K to this prospectus supplement. This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not bedelivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectussupplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in theProspectus and this prospectus supplement, you should rely on the information in this prospectus supplement. The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On April 10, 2026, the last reported saleprice of the ADSs on Nasdaq was $8.82 per ADS. Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus and the“Risk Factors” in “Item 3. Key Information-D. Risk Factors” of our most recent Annual Report on Form 20-F, which isincorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicableprospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to thecontrary is a criminal offense. The date of this prospectus supplement is April 13, 2026 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 000-29962 Kazia Therapeutics Limited.(Exact Name of Registrant as Specified in Its Charter) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000(Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F☒Form 40-F☐ INFORMATION CONTAINED IN THIS FORM 6-K REPORT Entry into Material Definitive Agreement This report on Form 6-K (the “Report”) contains information regarding the entry into a material definitive agreement by KaziaTherapeutics Limited (the “Company”). On April 10, 2026, the Company entered into a License and Commercialisation Agreement(the “Agreement”) with QIMR Berghofer Medical Research Institute (“QIMR Berghofer”), pursuant to which the Company obtainedan exclusive, worldwide license to research, develop, manufacture, and commercialize products based on QIMR Berghofer’sproprietary SETDB1-targeted epigenetic platform. Under the terms of the Agreement, the Company will pay QIMR Berghofer an upfront license fee of $1,390,000 within 15 businessdays of execution. The Agreement also provides for the Company to pay QIMR Berghofer a percentage of commercialization revenuereceived by the Company or its affiliates, with the specific percentage varying based on the stage of development at which any productis out-licensed to a third party. The Company has agreed to use commercially reasonable efforts to develop and commercialize at leastone product under the licensed intellectual property. About the SETDB1 Platform SETDB1 is a histone methyltransferase that plays a key role in gene silencing. In cancer, overexpression of SETDB1 is associatedwith suppression of immune signaling pathways and resistance to immunotherapy. The licensed platform includes proprietaryintellectual property directed to the inhibition of SETDB1 as a therapeutic strategy to restore immune function in tumors and enhancethe efficacy of cancer treatments. The Company believes this platform complements its existing oncology pipeline by targeting cancerresistance mechanisms at the chromatin level. Press Release The Company is furnishing with this Report on Form 6-K a press release announcing the transaction, dated April 13, 2026, as Exhibit99.1. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quotes of Dr.John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company’s registration statements on FormF‑3 (File Nos.333‑276091,333‑281937and333‑294392). EXHIBIT INDEX The following exhibits are furnished as part of this Form 6-K: ExhibitDescription99.1Press Relea